Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last weekend in the New England Journal of Medicine (NEJM).
AIDS Healthcare Foundation (AHF) and Ryan White Clinics for 340B Access (RWC-340B) executives separately highly criticized the article (subscription required) for tarring the 340B program and the clinicians who decide which PrEP medicines to prescribe. Drug companies that set PrEP prices and make PrEP patient assistance and reimbursement decisions are the problem, not 340B, both groups said.
Overreliance on 340B drug discount revenues to fund HIV-prevention services incentivizes clinics to prescribe high-cost medicines instead of cheaper effective options, “with dire consequences for [preexposure prophylaxis] PrEP access, impact, and equity,” says an opinion article published last weekend in the New England Journal of Medicine (NEJM).
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
